http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
신장이식환자를 위한 약물교육프로그램이 약물에 대한 지식과 약물복용 이행도에 미치는 효과
장정주(Jang, Jeong Ju),전정애(Jeun, Jeong Ah),박정숙(Park, Jeong Sook),성은혜(Sung, Eun Hae),김혜림(Kim, Hye Rim),조아람(Jo, A Ram) 계명대학교 간호과학연구소 2017 계명간호과학 Vol.21 No.1
Purpose: The purpose of this study was to analyze the effects of the drug educational program on knowledge and medication compliance for kidney transplantation patients. Methods: Kidney transplantation patients were recruited from a transplantation center, at a university hospital located in D city, Korea. Data were collected from June 18m 2016 to september 30, 2016. The research design was a nonequivalent one group pre-posttest. Nineteen subjects participated twice in a drug educational program given by the researcher. Results: After the intervention, the participants showed a significant increase in medication knowledge (t=-7.074, p<.001) and medication compliance (t=-4.553, p<.001) than before the intervention. Conclusion: The research findings suggest that a drug education program can be used as an effective nursing intervention for kidney transplantation patients.
Applicability of KEAP1 E3 Ligase to the PROTAC Platform
Raju Gurung(Raju Gurung),Jae Rim Lee(Jae Rim Lee),Min Ju Cho(Min Ju Cho),Jin Ah Jeong(Jin Ah Jeong),Sung Jean Park(Sung Jean Park),Kwang Won Jeong(Kwang Won Jeong),Dongyun Shin(Dongyun Shin) 대한약학회 2024 약학회지 Vol.68 No.4
Proteolysis-targeting chimeras (PROTACs) represent an innovative approach for drug design involving the creation of a heterobifunctional molecule. This molecule uses an E3 ligase to target and degrade specific proteins via the ubiquitin-proteasome system (UPS). The three essential components of PROTAC are a ligand for the protein of interest (POI), a binder to recruit an E3 ligase, and a linker connecting these two elements. Given the relatively large number of E3 ligases in the human body (>600), only a few such as VHL, CRBN, MDM2, cIAP1, DCAF15, RNF4, and RNF114 have been used in existing PROTACs. PROTACs facilitate degradation of pathological proteins through the UPS pathway. Consequently, the identification of a broad range of E3 ligase recruiters is crucial for advancing targeted protein degradation (TPD) strategies. In this study, we focused on designing KEAP1 binder PROTACs, using a selective, potent small-molecule inhibitor of KEAP1 as an E3 ligase recruiter. It was linked to JQ1 (a POI ligand) via a flexible aliphatic linker. Our compound SD-2406, with KEAP1 E3 ligase recruiter, effectively degraded BRD4 target proteins in LNCaP cells. This demonstrates the potential of expanding the E3 ligase toolbox for the development of PROTAC technology.
Jeong-Ju Yoo,Soo Young Park,Ji Eun Moon,Yu Rim Lee,Han Ah Lee,Jieun Lee,Young Seok Kim,Yeon Seok Seo,Sang Gyune Kim 대한간학회 2023 Clinical and Molecular Hepatology(대한간학회지) Vol.29 No.2
Background/Aims: The histologic status of the immune-tolerant (IT) phase of chronic hepatitis B relative to long-term outcomes is unclear. This study aimed to discover how the serological criteria currently in use correspond to histologic criteria in determining the IT phase and indication for liver biopsy. Methods: Patients in the serological IT phase determined by positive hepatitis B e antigen, hepatitis B virus (HBV) DNA ≥106 IU/mL, and normal or minimally elevated alanine aminotransferase (ALT) ≤60 IU/L, who underwent liver biopsy at three different hospitals were included. The distribution of the histologic IT phase, defined as fibrosis of stage 1 or less and inflammation of grade 1 or less, was compared with that of the serological IT phase. The risk factors for the incidence of liver-related events, such as hepatocellular carcinoma, liver cirrhosis, liver transplantation, and death, were also analyzed. Results: Eighty-two (31.7%) out of 259 clinically suspected IT phase patients belonged to the histologic IT phase. Age over 35, high AST, and low albumin were useful for ruling out the histologic IT phase. Risk factors predicting liver-related events were age and significant fibrosis stage. There was no significant difference in the proportion of histologic IT phase and clinical prognosis between normal ALT and mildly elevated ALT groups. However, even in patients with normal ALT, age was an important factor in predicting the presence of the histologic IT phase. Conclusions: A significant number of patients who belonged to the serological IT phase were not in the histologic IT phase. Patients over 35 years and those with high AST, low albumin, and low HBV DNA levels were more likely to experience poor long-term clinical outcomes. Therefore, additional histologic assessment should be considered.
Anti-inflammatory Effect of Columbianetin on Activated Human Mast Cells
Jeong, Hyun-Ja,Na, Ho-Jeong,Kim, Su-Jin,Rim, Hong-Kun,Myung, Noh-Yil,Moon, Phil-Dong,Han, Na-Ra,Seo, Jae-Uk,Kang, Tae-Hee,Kim, Jae-Joong,Choi, Youngjin,Kang, In-Cheol,Hong, Seung-Heon,Kim, You-Ah,Seo, Pharmaceutical Society of Japan 2009 BIOLOGICAL & PHARMACEUTICAL BULLETIN Vol.32 No.6
<P>In the present study, we extracted <I>Corydalis heterocarpa</I> with various solvents in order to find the bioactive constituents that demonstrated anti-inflammatory effects. We isolated the active compound, Columbianetin. Anti-inflammatory effect of Columbianetin has been reported but the precise effects of Columbianetin in experimental models have remained unknown. In the present study, we investigate the effect of Columbianetin on the production of histamine, interleukin (IL)-1β, IL-6, IL-8, and tumor necrosis factor (TNF)-α and expression of cyclooxygenase-2 (COX-2) by using the human mast cell line (HMC-1). Various concentrations of Columbianetin were treated before the activation of HMC-1 cells with phorbol 12-myristate 13-acetate (PMA) plus calcium ionophore, A23187. PMA plus A23187 significantly increased IL-1β, IL-6, IL-8, and TNF-α production compared with media control (<I>p</I><0.05). We also show that the increased cytokines IL-1β, IL-6, IL-8, and TNF-α level was significantly inhibited by Columbianetin in a dose-dependent manner (<I>p</I><0.05). Maximal inhibition rates of IL-1β, IL-6, IL-8, and TNF-α production by Columbianetin were about 102.6%, 101.1%, 95.8%, and 103.9%, respectively. Columbianetin inhibited expression of COX-2. In addition, the effect of Columbianetin was investigated on the histamine release from HMC-1 stimulated by substance P, which promotes histamine release. Columbianetin also inhibited the histamine release by substance P. In conclusion, these results indicate that Columbianetin may be helpful in regulating mast cell-mediated allergic inflammatory responses.</P>